Hutchison China Meditech Ltd (HCM)

 

HCM Share PerformanceMore

52 week high3,690.00 21/06/17
52 week low1,760.00 25/08/16
52 week change 1,585.00 (84.08%)
4 week volume94,965 26/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Total Voting Rights

RNS Number: 6992J Hutchison China Meditech Limited 30 June 2017 Total Voting Rights London: Friday, June 30, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at June 30, 2017, the issued share capital of Chi-Med consisted of 60,737,204 ordinary shares of US$1.00 each, with ea...

Chi-Med and AZ start global trial of renal cancer drug

Hutchison China MediTech and AstraZeneca have initiated a global pivotal phase III, open-label, randomised multi-centre r...

Blocklisting Six Monthly Return

RNS Number: 4737J Hutchison China Meditech Limited 29 June 2017 Blocklisting Six Monthly Return London: Thursday, June 29 , 201 7: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchison China Medi...

Start of Savolitinib Global PRCC Phase III Trial

RNS Number: 5372J Hutchison China Meditech Limited 29 June 2017 Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma London: Thursday, June 29, 2017: Chi-Med and AstraZeneca today announce that they have initiated a global pivotal Phase III, open-label, randomized multi-center registration study...

Chi-Med to Announce 2017 HY Financial Results

RNS Number: 4680J Hutchison China Meditech Limited 29 June 2017 Chi-Med to Announce 201 7 Half-Year Financial Results London: Thurs day , Ju ne 29 , 201 7: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 201 7 on Mon day, July 31 , 201 7 at 7:00 am British Summer T...

Chi-Med starts clinical trial in China

Hutchison China MediTech has initiated a phase I/II clinical trial of HMPL453 in China. Chi-Med said HMPL453 was a nov...

Chi-Med starts Ph I/II Trial of HMPL 453 in China

RNS Number: 8432I Hutchison China Meditech Limited 22 June 2017 Press Release ChiMed Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL453 in China London: Thursday , June 22, 2017: Hutchison China MediTech Limited ("ChiMed") (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL453 in China. HMPL453 is a novel, highly...

Director's Share Dealing

RNS Number: 3179I Hutchison China Meditech Limited 16 June 2017 Director's Share Dealing London: Friday, June 16 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:- 1. Dynamic Drive Limited, a person closely associated ("PCA") with Mr Simon To, Executive Director and Chairman, purchased a total of 11,1...

Equity Research (HCM)

edison investment research
Hutchison China MediTech Limited
13/06/2017
At ASCO, Hutchison China MediTech (HCM) presented detailed Phase III trial results for one of its leading assets, fruquintinib (third-line colorectal cancer). Full data from the China-based FRESCO...
edison investment research
Hutchison China MediTech Limited
13/06/2017
At ASCO, Hutchison China MediTech (HCM) presented detailed Phase III trial results for one of its leading assets, fruquintinib (third-line colorectal cancer). Full data from the China-based FRESCO...
edison investment research
Hutchison China MediTech Limited
11/05/2017
Despite a strong run over the last 12 months, our increased valuation of $2.7bn suggests the market overlooks HCM’s full R&D potential. Multiple catalysts are on the horizon in 2017/18; notably...

Latest discussion posts More

  • Seeking Alpha Update 12th July

    https://seekingalpha.com/article/4087275-chinese-oncology-company-great-potential?auth_param=1dk0ei:1cmclhp:1f288d3bb15c78e187ced953dcba7e21&uprof=45&dr=1 "The relative ...
    13-Jul-2017
    David Global
  • Re: Celgene buys 5.9% Beigene

    Having listened to the Beigene call yesterday it is clear that big U.S. Pharma are looking to do deals with smaller late stage Biotechs Watch this space for a similar major ...
    7-Jul-2017
    David Global
  • Celgene buys 5.9% Beigene

    https://stocktwits.com/symbol/BGNE Beigene are a much smaller equivalent to us who also had a recent NASDAQ IPO. Now pre-market price on NASDAQ shows them with a larger ...
    6-Jul-2017
    David Global

Users' HoldingsMore

Users who hold Hutchison China Meditech Ltd also hold..
RDS 'B'24%
NATIONAL GRID21%
GLAXOSMITHKLINE20%
LLOYDS GRP.18%
BP17%

Codes & Symbols

ISINKYG4672N1016
SymbolsHCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM